Targeted radio-immunotherapy for metastatic prostate cancer

International Conference on Nuclear Medicine & Radiation Therapy

July 14-15, 2016 Cologne, Germany

Barry J Allen

University of Western Sydney, Australia

Posters & Accepted Abstracts: J Nucl Med Radiat Ther

Abstract :

Prostate cancer claimed an estimated 136,500 lives globally in 2011. Recurrent disease is usually treated with androgen deprivation therapy (ADT), which provides outstanding early but transient control of progression. The tragedy here is that the benefits of ADT are lost within 2 years for most men as the cancer progresses to an incurable â�?�?late-stageâ�? castrate resistant form of the disease (CRPC) with median survival of ~18 months. The minimal residual disease states derived from prostatectomy and ADT provide clear windows of opportunity for an effective systemic adjuvant therapy with minimal side effects. Targeted alpha therapy (TAT) is such a therapy, where antibodies specific for cancer biomarkers are labeled with alpha-radionuclides to more efficiently kill cancer cells with reduced adverse events. The success of systemic TAT in clinical trials for advanced metastatic melanoma indicates efficacy with minimal side effects. Improved molecular profiling of tumors now allows for therapies like TAT to be personalized for the patientâ�?�?s cancer, leading to the next generation of adjuvant for the treatment of minimal residual disease states following prostatectomy and ADT. This paper examines the preclinical and clinical efficacy of TAT with c595 and J591 monoclonal antibodies, labeled with beta or alpha emitting radioisotopes, and its potential as an adjunctive therapy for the management of residual prostate cancer.

Biography :

Email: bja1940@optusnet.com.au